[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349645-105":59,"doc-detail-349645-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","recurrent-mechanisms-of-biallelic-epigenetic-inactivation-reveal-new-putative-tumour-suppressor-genes-in-prostate-cancer","Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer","","Recurrent mechanisms of biallelic epigenetic inactivation drive the discovery of previously unrecognized tumour suppressor genes in prostate cancer. The work addresses the challenge that large genomic regions are often hemizygously lost, obscuring the identification of biallelic tumour suppressors. It introduces Epi2Hit, an integrative computational framework combining whole-genome sequencing, epigenomic profiling, and gene expression to detect promoter/enhancer DNA methylation on one allele with genomic loss on the other. Applied to 2,021 prostate cancers, it highlights epigenetic biallelic inactivation of ZFHX3 with oncogene upregulation and earlier metastasis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recurrent-mechanisms-of-biallelic-epigenetic-inactivation-reveal-new-putative-tumour-suppressor-genes-in-prostate-cancer/349645/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recurrent-mechanisms-of-biallelic-epigenetic-inactivation-reveal-new-putative-tumour-suppressor-genes-in-prostate-cancer/349645.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in identifying tumour suppressor genes in prostate cancer?","Question",{"text":112,"@type":113},"Prostate cancer often shows hemizygous loss of large genomic regions, which makes it difficult to distinguish biallelic tumour suppressors from single-allele events.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does Epi2Hit detect biallelic epigenetic inactivation?",{"text":117,"@type":113},"Epi2Hit integrates whole-genome sequencing and epigenomic and expression data to find cases where one allele has promoter/enhancer DNA methylation while the other allele has genomic loss.",{"name":119,"@type":110,"acceptedAnswer":120},"Which gene is highlighted as having recurrent epigenetic biallelic inactivation, and what are the consequences?",{"text":121,"@type":113},"The study identifies ZFHX3 as epigenetically inactivated at a recurrence level comparable to TP53; its biallelic inactivation leads to oncogene upregulation, including MYC, and a shorter time to metastasis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349645,1790838461,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Article [https://doi.org/10.1038/s41467-026-72182-5](https://doi.org/10.1038/s41467-026-72182-5)  \nRecurrent mechanisms ofbiallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer  \nReceived: 19 February 2025  \nAccepted: 9 April 2026  \n\n| Published online: 9 September 2026 |\n| --- |\n| Check for updates |\n\nA list of authors and their afﬁliations appears at the end of the paper  \nThe inactivation of tumour suppressor genes is a key step in cancer development, and is usually achieved by homozygous loss. In prostate cancer, however, large genomic regions are often hemizygously lost, which complicates the identiﬁcation of putative tumour suppressors in these regions. Here, we develop Epi2Hit, an integrative computational method that leverages whole genome sequencing, epigenomic proﬁling and gene expression to identify biallelic inactivation of tumour suppressor genes involving DNA methylation of promoter and enhancer regions of one allele and genomic loss of the other allele. We apply Epi2Hit to a cohort of 2,021 prostate cancers to discover tumour suppressor genes. In particular, we identify epigenetic biallelic inactivation of ZFHX3 at a recurrence level similar to TP53. Biallelic inactivation of ZFHX3, a transcriptional repressor, leads to upregulation of oncogenes, including MYC and a shorter time to metastasis. Finally, we provide evidence that epigenetic silencing as 2nd hit is particularly enriched in regions with nearby essential genes, precluding homozygous loss.  \nProstate cancer is the second most frequent type of cancer in men worldwide1,2. The disease is highly heterogeneous at the molecular level, with a paucity of somatic single nucleotide variant (SNVs) drivers but frequent structural variations (SVs), which commonly cause copy number losses3. Approximately 10% of the prostate cancer genome is recurrently lost in more than 20% of prostate cancer tumours, but only a subset of these harbour known prostate cancer driver genes4–7.  \nTumour suppressor genes (TSG) often undergo biallelic inactivation in various cancer types including prostate cancer8–11. The landmark Two-Hit hypothesis posited by Knudson forms the cornerstone of our understanding of TSGs. It suggests that the path towards malignancy is often paved by the sequential inactivation of both alleles of a gene12. This is true for prostate cancer, where TSGs such as PTEN, TP53, CHD1 and BRCA1/2 are frequently biallelically inactivated by a combination of copy number loss and SNVs13–15. Biallelic inactivation can, however, be highly complex, involving different inactivating germline and somatic events.  \nEpigenetic silencing by e.g. hypermethylation of promoter and enhancer regions ofTSGs is an alternative mechanism of inactivation, often coinciding with genomic inactivation of the other allele. Biallelic  \ninactivation involving copy number loss of one allele and epigenetic silencing of the other allele remains poorly explored except for a few prominent examples including MLH1 (in colorectal cancer and endometrial cancer)16,17, BRCA1 (breast and ovarian cancer)18–20, MGMT (glioma)21,22 and APC (various cancers including prostate cancer)23–26. Several of these examples represent established prognostic or predictive biomarkers. Despite its recognised signiﬁcance, a comprehensive methodology to elucidate the multifaceted nature of biallelic inactivation within this context has remained elusive, constraining our insights into disease progression and the implicated genes, as previous studies were limited to smaller gene panels, low-resolution methodologies, or lack of systematic integration of genomic alterations, DNA methylation, and expression27,28.  \nTo discover and explore the spectrum and magnitude of epigenetic biallelic inactivation in prostate cancer, we develop and apply a computational methodology, Epi2Hit, which integrates hemizygous genomic disruptions with hypermethylation at regulatory CpG sites to identify bialleli","cbCaiffkALWTYabq","https://ap.wps.com/l/cbCaiffkALWTYabq","pdf",3750850,"English","# Results\n## Methodology to discover Epi2Hit in prostate cancer","[{\"question\":\"What problem does the study address in identifying tumour suppressor genes in prostate cancer?\",\"answer\":\"Prostate cancer often shows hemizygous loss of large genomic regions, which makes it difficult to distinguish biallelic tumour suppressors from single-allele events.\"},{\"question\":\"How does Epi2Hit detect biallelic epigenetic inactivation?\",\"answer\":\"Epi2Hit integrates whole-genome sequencing and epigenomic and expression data to find cases where one allele has promoter/enhancer DNA methylation while the other allele has genomic loss.\"},{\"question\":\"Which gene is highlighted as having recurrent epigenetic biallelic inactivation, and what are the consequences?\",\"answer\":\"The study identifies ZFHX3 as epigenetically inactivated at a recurrence level comparable to TP53; its biallelic inactivation leads to oncogene upregulation, including MYC, and a shorter time to metastasis.\"}]","Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer | PDF",1790084680,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c40d0faecc7ea8e669971ed2aa43faa6.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82df389c532c9c3968e5748cdd225431.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8653e9b6ec2a6d1cd0ab75fe31d0aaef.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d46d5aba362b7c883b7d5e0e163ccb46.webp",980,1301]